Back to Search
Start Over
Serum Elabela expression is decreased in hypertensive patients and could be associated with the progression of hypertensive renal damage
- Source :
- European Journal of Medical Research, Vol 29, Iss 1, Pp 1-7 (2024)
- Publication Year :
- 2024
- Publisher :
- BMC, 2024.
-
Abstract
- Abstract Background Elabela, a recently discovered hormonal peptide containing 32 amino acids, is a ligand for the apelin receptor. It can lower blood pressure and attenuate renal fibrosis. However, the clinicopathological relationship between Elabela level and renal damage caused by benign hypertension (BHT) and malignant hypertension (MHT) has not been elucidated. Therefore, we investigated the clinicopathological correlation between serum Elabela level and renal damage caused by BHT and MHT. Methods The participants comprised 50 patients and 25 age-matched healthy adults. The 50 patients were separated into two groups: MHT (n = 25) and BHT groups (n = 25). We analyzed their medical histories, demographics, and clinical examinations, including physical and laboratory tests. Results The results showed that serum Elabela level decreased gradually with a continuous increase in blood pressure from the healthy control group, BHT, to MHT. Moreover, Elabela levels negatively correlated with BMI (R = − 0.27, P = 0.02), SBP (r = − 0.64, P
Details
- Language :
- English
- ISSN :
- 2047783X
- Volume :
- 29
- Issue :
- 1
- Database :
- Directory of Open Access Journals
- Journal :
- European Journal of Medical Research
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.64701be8e81248ad975e91ae05646711
- Document Type :
- article
- Full Text :
- https://doi.org/10.1186/s40001-024-01674-1